darolutamide (Nubeqa)
Jump to navigation
Jump to search
Indications
- nonmetastatic, castration-resistant prostate cancer
- metastatic hormone-sensitive prostate cancer[3]
Dosage
Adverse effects
- most common
- other
- ischemic heart disease (4.3%)
- heart failure (2.1%)
Clinical trials
- reduces morality in castration-resistant prostate cancer
More general terms
References
- ↑ FDA Announcement. July 30, 2019 FDA approves darolutamide for non-metastatic castration- resistant prostate cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer
- ↑ Fizazi K et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020 Sep 10; 383:1040. PMID: https://pubmed.ncbi.nlm.nih.gov/32905676 https://www.nejm.org/doi/10.1056/NEJMoa2001342
- ↑ 3.0 3.1 Friedman J, Biele H FDA expands darolutamide indication for advanced prostate cancer. Healio. June 4, 2025 https://www.healio.com/news/hematology-oncology/20250604/fda-expands-darolutamide-indication-for-advanced-prostate-cancer